Target Oncol: Real-world exploration of the efficacy of Crizotinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)

On March 11, 2016, Crizotinib became the first oral targeted therapy approved by the U.
S.
Food and Drug Administration (FDA) for c-ros oncogene 1 (ROS1)-positive advanced non-small cell lung cancer (NSCLC).
) drugs
.
However, its data in the real world is still relatively limited .

Therefore, a team from the United States conducted a relevant real-world study to evaluate the efficacy of Crizotinib (crizotinib) in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) .

On March 11, 2016, Crizotinib became the first oral targeted therapy approved by the U.

The study primarily used Kaplan Meier analysis to assess time to treatment to discontinuation (TTD), time to next treatment (TTNT), and overall survival (OS)
.
Cox proportional hazards models were used to determine factors associated with OS

.

The study primarily used Kaplan Meier analysis to assess time to treatment to discontinuation (TTD), time to next treatment (TTNT), and overall survival (OS)

The study finally included 38 ROS 1-positive patients who received crizotinib .

Overall, 21 (55.

Ten (26.
3%) patients received subsequent treatment

.

Ten (26.

The median OS at initiation of crizotinib was 36.

2 months (95% CI 15.

The median OS at initiation of crizotinib was 36.

Risk of death in patients with ECOG=2 compared with patients with ECOG=0 or 1 in Cox regression analysis, after controlling for age, smoking status, BMI, and time between diagnosis of non-small cell lung cancer and initiation of crizotinib treatment 4.

9-fold increase (HR = 4.

Risk of death in patients with ECOG=2 compared with patients with ECOG=0 or 1 in Cox regression analysis, after controlling for age, smoking status, BMI, and time between diagnosis of non-small cell lung cancer and initiation of crizotinib treatment 4.
9-fold increase (HR = 4.
9; 95%CI 1.
1 21.
4; P = 0.
0337)
.
Likewise, patients with current/former smoking status were associated with a 6.
0-fold increased risk of death compared with never-smokers (HR = 6.
0; 95% CI 1.
2 30.
8; P = 0.
0326)
.
Risk of death in patients with ECOG=2 compared with patients with ECOG=0 or 1 in Cox regression analysis, after controlling for age, smoking status, BMI, and time between diagnosis of non-small cell lung cancer and initiation of crizotinib treatment 4.
9-fold increase (HR = 4.
9; 95%CI 1.
1 21.
4; P = 0.
0337)
.
Likewise, patients with current/former smoking status were associated with a 6.
0-fold increased risk of death compared with never-smokers (HR = 6.
0; 95% CI 1.
2 30.
8; P = 0.
0326)
.

Taken together, the study showed that Crizotinib can improve patient outcomes despite a higher proportion of middle-aged, older, smoking, and poorer patients in real-world ROS1-positive NSCLC patients than in clinical trials
.

Taken together, the study showed that Crizotinib can improve patient outcomes despite a higher proportion of middle-aged, older, smoking, and poorer patients in real-world ROS1-positive NSCLC patients than in clinical trials
.
The study showed that Crizotinib improved patient outcomes despite a higher proportion of middle-aged, smoked, and poorer patients with ROS1-positive NSCLC in the real world than in clinical trials
.
The study showed that Crizotinib improved patient outcomes despite a higher proportion of middle-aged, smoked, and poorer patients with ROS1-positive NSCLC in the real world than in clinical trials
.

 

Original source:

Original source:

Waterhouse D, Iadeluca L, Sura S, Wilner K, Emir B, Krulewicz S, Espirito J, Bartolome L.
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology- Based Observational Study.
Target Oncol.
2022 Jan;17(1):25-33.
doi: 10.
1007/s11523-021-00860-z.
Epub 2021 Dec 29.
PMID: 34964940; PMCID: PMC8783880.

Waterhouse D, Iadeluca L, Sura S, Wilner K, Emir B, Krulewicz S, Espirito J, Bartolome L.
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology- Based Observational Study.
Target Oncol.
2022 Jan;17(1):25-33.
doi: 10.
1007/s11523-021-00860-z.
Epub 2021 Dec 29.
PMID: 34964940; PMCID: PMC8783880.
Leave a message here